Is the FDA Too Cautious?
Open to Debate
The FDA's Accelerated Approval of the Alzheimer Drug
FDA gave accelerated approval to a drug where the evidence wasn't there, and their own advisory committee voted against it. The problem is that studies take a long time to get done; moreover, drugs do come to market and they turn out to be non-confermatory. "The issue in the FDA is not to approve or not approve fast or not," says Dr. Colin Rieckhoff.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
